Comparison of Inhaled Ciclesonide (160 mcg b.i.d. or 320 mcg b.i.d.) and Fluticasone Propionate (250 mcg b.i.d. or 500 mcg b.i.d.) in Pretreated Patients With Mild to Moderate Asthma

AstraZeneca1 site in 1 country30 target enrollmentMarch 2003

ConditionsAsthma

DrugsCiclesonide

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Asthma
Sponsor: AstraZeneca
Enrollment: 30
Locations: 1
Primary Endpoint: AUC(0-24h)/24 h of serum cortisol level
Status: Completed
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The aim of the study is to investigate the effect of ciclesonide versus fluticasone propionate versus placebo on airway hyperresponsiveness and on the hypothalamic-pituitary-adrenal axis (HPA axis). Treatment medication will be administered as follows: ciclesonide or fluticasone propionate will be inhaled twice daily, using one of the two dose levels. The study duration consists of a baseline period (4 to 6 weeks), five treatment periods (9 days each), and a washout period between treatments (4 to 12 weeks). The study will provide further data on safety and tolerability of ciclesonide.

Registry

clinicaltrials.gov

Start Date

March 2003

End Date

TBD

Last Updated

9 years ago

Study Type

Interventional

Study Design

Crossover

Sex

All

Investigators

Sponsor

AstraZeneca

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients who have had a history of bronchial asthma for at least 6 months
•FEV1 \>60% of predicted for at least 24 h
•Patients who are hyperresponsive to methacholine and to AMP
•Patients who are in good health with the exception of asthma

Exclusion Criteria

•Concomitant severe diseases or diseases which are contraindications for the use of inhaled steroids
•Patients suffering from COPD and/or other relevant lung diseases except asthma
•Current smokers and ex-smokers both with ≥10 pack years